Osimertinib vs Rezivertinib

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: EGFR · full Non-Small Cell Lung Cancer pipeline

Osimertinib · Tagrisso

Marketed by AstraZeneca

Approved in Non-Small Cell Lung Cancersmall molecule
Partial signal

NCT02151981 · Phase 3 · completed

The trial was randomized and actively controlled, with 279 patients receiving osimertinib and 140 receiving platinum-based chemotherapy, but treatment assignment was not blinded. Its primary clinical endpoint, investigator-assessed progression-free survival, favored osimertinib significantly (hazard ratio 0.30; p<0.001), supporting moderate-strength evidence rather than the strongest level because the study was open-label.

Next expected readout: November 2026 · NCT05998993 (registry estimate)

Reported efficacy

Progression Free Survival (PFS) by Investigator Assessment (RECIST tumour assessments every 6 weeks from randomisation until objective disease progression up to 19 months (at the time of the primary PFS analysis).): Progression Free Survival (PFS) by Investigator Assessment (RECIST tumour assessments every 6 weeks from randomisation until objective disease progression up to 19 months (at the time of the primary PFS analysis).): Osimertinib 80mg 10.1 Months (95% CI 8.3 to 12.3) | Chemotherapy 4.4 Months (95% CI 4.2 to 5.6) (met)

Result source: NCT02151981

Rezivertinib

Marketed by Beta Pharma, Inc.

Phase 3 in Non-Small Cell Lung Cancersmall molecule
Reliable signal

NCT03866499 · Phase 3 · status unknown

This trial randomized 369 patients to BPI-7711 or active-controlled gefitinib with full blinding of participants, care providers, investigators, and outcome assessors, testing a hard clinical endpoint (progression-free survival) that is standard for regulatory approval in NSCLC. The primary comparison was statistically significant and favored BPI-7711, with a nearly doubled median PFS and a strong hazard ratio, supporting confidence in the result.

Next expected readout: December 2030 · NCT06955325 (registry estimate)

Reported efficacy

Progression-free survival (up to approximately 16 months): REZOR (NCT03866499), primary endpoint median PFS: rezivertinib (BPI-7711) 19.3 months vs gefitinib 9.6 months; HR 0.48 (95% CI 0.36-0.63); p<0.0001 (met)

Result source: NCT03866499

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointOsimertinibRezivertinib
PFS, median19.5 vs 22.0vs Gefitinibn 45NCT02856893
1 other result
—Trial running · NCT06955325
OS, median—Not posted · NCT05015608—Trial running · NCT06955325
ORR76%bn 25NCT02789345—Trial running · NCT06955325
Duration of response, median13.4bn 19NCT02789345—Trial running · NCT06955325

PFS, median

Osimertinib
19.5 vs 22.0vs Gefitinibn 45NCT02856893
1 other result
Rezivertinib
—Trial running · NCT06955325

OS, median

Osimertinib
—Not posted · NCT05015608
Rezivertinib
—Trial running · NCT06955325

ORR

Osimertinib
76%bn 25NCT02789345
Rezivertinib
—Trial running · NCT06955325

Duration of response, median

Osimertinib
13.4bn 19NCT02789345
Rezivertinib
—Trial running · NCT06955325
  1. b Single-arm result: the trial had no control arm, so the number has no comparator and does not compare with a randomised result.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Rezivertinib
REZOR (NCT03866499), primary endpoint median PFS: rezivertinib (BPI-7711) 19.3 months vs gefitinib 9.6 months; HR 0.48 (95% CI 0.36-0.63); p<0.0001 NCT03866499 · Phase 3 · design grade: strong · publication or press release
ORR by blinded independent central review 64.6% (95% CI 58.0%-70.8%) NCT03812809 · Phase 2 · design grade: weak · publication or press release

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Osimertinib: 4 of 4 rows · Rezivertinib: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricOsimertinib
Dropout rate
62.3%a
NCT02856893 · Phase 2 · registry result, not featured evidence
show 2 more results
100%Arm A: Ramucirumab + Osimertinib
NCT02789345 · Phase 1 · registry result, not featured evidence · combination
77.3%Cohort A: Ramucirumab + Osimertini
NCT02789345 · Phase 1 · registry result, not featured evidence · combination
Discontinued due to AEs
3.8%a
NCT02856893 · Phase 2 · registry result, not featured evidence
show 2 more results
0%Arm A: Ramucirumab + Osimertinib
NCT02789345 · Phase 1 · registry result, not featured evidence · combination
4.5%Cohort A: Ramucirumab + Osimertini
NCT02789345 · Phase 1 · registry result, not featured evidence · combination
Serious AEs
17%a
NCT02856893 · Phase 2 · registry result, not featured evidence
show 2 more results
33.3%Arm A: Ramucirumab + Osimertinib
NCT02789345 · Phase 1 · registry result, not featured evidence · combination
36.4%Cohort A: Ramucirumab + Osimertini
NCT02789345 · Phase 1 · registry result, not featured evidence · combination
Most frequent reported AEs
a
diarrhea 50.9%
dry skin 41.5%
weight loss 35.8%
NCT02856893 · Phase 2 · registry result, not featured evidence
show 2 more results
cough 100%
diarrhoea 100%
arthralgia 66.7%
NCT02789345 · Phase 1 · registry result, not featured evidence · combination
diarrhoea 63.6%
hypertension 63.6%
decreased appetite 40.9%
NCT02789345 · Phase 1 · registry result, not featured evidence · combination

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Osimertinib

PFS18 51.1% (n=45) vs 67.2% (n=47) Gefitinib @ 78wk
responder rate · % of participants
NCT02856893 · Phase 2 · registry result, not featured evidence
PFS 19.48 vs 21.98 Gefitinib months
time to event · months
NCT02856893 · Phase 2 · registry result, not featured evidence
Time to Progression 19.48 vs 10.81 Gefitinib months
time to event · months
NCT02856893 · Phase 2 · registry result, not featured evidence
ORR 0.889 vs 0.656 Gefitinib count
event count · count
NCT02856893 · Phase 2 · registry result, not featured evidence
Overall Survival NA vs NA Gefitinib months
time to event · months
NCT02856893 · Phase 2 · registry result, not featured evidence
Intracranial PFS 34.3 vs 24.44 Gefitinib months
absolute value · months
NCT02856893 · Phase 2 · registry result, not featured evidence
PFS2 25.76 vs 21.98 Gefitinib months
time to event · months
NCT02856893 · Phase 2 · registry result, not featured evidence
ORR 76% (n=25)
responder rate · % of participants
No placebo or comparator arm
NCT02789345 · Phase 1 · registry result, not featured evidence · combination
Disease Control 92% (n=25)
responder rate · % of participants
No placebo or comparator arm
NCT02789345 · Phase 1 · registry result, not featured evidence · combination
Duration of Response 13.37 months
time to event · months
No placebo or comparator arm
NCT02789345 · Phase 1 · registry result, not featured evidence · combination
PFS 11.04 months
time to event · months
No placebo or comparator arm
NCT02789345 · Phase 1 · registry result, not featured evidence · combination
Overall Survival NA months
time to event · months
No placebo or comparator arm
NCT02789345 · Phase 1 · registry result, not featured evidence · combination

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Osimertinib's landscape · Rezivertinib's landscape